In a strategic move set to reshape the European biotech and science innovation landscape, the Novo Nordisk Foundation has pledged a long-term investment of up to DKK 5.5 billion (≈ €736 million) to the Copenhagen-based BioInnovation Institute (BII), extending support through 2035. This unprecedented investment will expand BII’s role in commercializing science, scaling startups, and building cross-sector bridges across Europe.
The commitment also signals a broader push to close Europe’s long-standing gap between world-class research and global commercial leadership in emerging technologies.
From Seedbed to Scale-Up Powerhouse
Since its launch in 2018, BII has proven itself as a launchpad for deep science ventures. Through flagship programs like Venture Lab, Bio Studio, and the BII Quantum Lab, the institute has helped create more than 130 startups and has been instrumental in attracting over DKK 7 billion in external funding from venture capital and strategic partners.
This latest infusion of capital marks a decisive leap from a successful national ecosystem player to a European-stage innovation backbone, one capable of supporting a year-over-year increase in early-stage ventures and enabling deeper, interdisciplinary breakthroughs.
Europe consistently produces world-class research across biology, biomedicine, and physical sciences. Yet, globally, fewer European discoveries mature into market-ready products, high-growth enterprises, and economic impact compared with the U.S. and Asia. The Novo Nordisk Foundation’s strategic investment underscores an urgent recognition: scientific excellence alone isn’t enough. It must be paired with robust commercialization infrastructure.
BII’s expanded mandate is explicitly designed to tackle this gap, pushing beyond support for classic life science startups to include adjacent frontiers like artificial intelligence and quantum technologies, fields that are increasingly convergent with biotechnology in drug discovery, diagnostics, and bio-manufacturing.
More Than Money: A Blueprint for Next-Gen Innovation
The new funding framework running from 2026 to 2035 signals confidence in BII’s model and unlocks predictability, a rare commodity for early-stage innovators. Unlike grant programs with rolling annual applications or shifting priorities, this long-horizon commitment gives startups, investors, and academic partners certainty that the institute will remain a stable bridge from lab to marketplace.
BII’s core programs also reflect this dual focus:
- Venture Lab: Helps translate scientific discoveries into commercially viable startups.
- Bio Studio: Supports academic founders and translational research projects.
- BII Quantum Lab: Seeks to fuse cutting-edge compute technologies with biological problems, opening doors to new industry categories.
With this financial runway, BII is expected to nearly double its annual startup support, fostering an environment where ambitious founders can tackle systemic challenges, from drug resistance to sustainable bioproduction, without being bottlenecked by early capital scarcity.
The expansion strategy also leans heavily on collaboration. BII’s ecosystem today already includes high-impact partners, including commercial, philanthropic, and academic partners. Examples include joint initiatives with major industry players and foundations to address women’s health and brain disease, as well as investments in early-stage technologies shaping future energy and material systems.
Leading BII’s charge, CEO Jens Nielsen has emphasized that no single institution can close Europe’s innovation gap alone. Strengthening international partnerships and linking localized innovation districts to broader European networks will be critical to building scale and attracting global capital.
A Landmark Moment for European Innovation Policy
Industry observers view this announcement as a watershed moment for European innovation policy. With sustained funding, BII is poised to become a key node in Europe’s biotech infrastructure, catalyzing not just Danish science but a continent-wide ecosystem where ideas translate into impact.
By anchoring this investment in both traditional life sciences and cutting-edge deep tech, the Novo Nordisk Foundation and BII are betting on an integrated future where computational power, biological insight, entrepreneurial agility, and deep pockets converge in an effort to solve global challenges.
Related: Global Database of Regenerative Medicine (RM) Industry Investors – Featuring 300+ Investors
